InnoCare Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	6,189	7,072	6,241	8,287	8,698	5,929
Trading Asset Securities	902.84	-	759.18	-	313.29	317.06
Cash & Short-Term Investments	7,092	7,072	7,000	8,287	9,011	6,246
Cash Growth	1.20%	1.03%	-15.53%	-8.04%	44.28%	57.34%
Accounts Receivable	488.39	502.88	351	276.38	127.83	45.27
Other Receivables	0.62	0	0.05	31.34	61.79	62.27
Receivables	489.01	502.88	351.05	307.71	189.61	107.55
Inventory	174.13	162.87	95.58	119.09	65.32	9.92
Other Current Assets	441.24	324.09	373.56	51.38	33.56	53.87
Total Current Assets	8,196	8,062	7,820	8,765	9,300	6,417
Property, Plant & Equipment	729.47	752.26	814.27	798.5	937.27	566.08
Long-Term Investments	649.24	1,201	0.4	5.66	11.71	326.1
Goodwill	3.12	3.12	3.12	3.12	3.13	3.13
Other Intangible Assets	247.69	248.05	258.14	266.03	41.31	34.17
Long-Term Deferred Charges	29.53	30.31	31.94	33.3	-	-
Other Long-Term Assets	527.89	526.24	479.43	48.06	28.04	50.95
Total Assets	10,383	10,824	9,407	9,920	10,321	7,398
Accounts Payable	210.55	183.7	128.36	134.9	118.6	84.6
Accrued Expenses	39.58	137.6	87.69	100.08	116.03	97.5
Short-Term Debt	388.29	176.93	137.45	-	-	-
Current Portion of Long-Term Debt	138.41	112.26	56.35	1,256	1,197	-
Current Portion of Leases	-	27.23	31.61	23.23	20.11	20.34
Current Income Taxes Payable	58.38	11.88	-	-	-	-
Current Unearned Revenue	34.6	105.43	-	-	12	19.48
Other Current Liabilities	580.91	628.72	607.82	567.64	611.52	107.39
Total Current Liabilities	1,451	1,384	1,049	2,082	2,075	329.3
Long-Term Debt	988	1,276	1,322	331.88	287.76	1,238
Long-Term Leases	17.5	19.03	27.44	43.65	35.44	47.44
Long-Term Unearned Revenue	285.58	289.42	263	281.78	278.2	123.61
Long-Term Deferred Tax Liabilities	-	106.51	-	-	-	-
Total Liabilities	3,020	3,074	2,662	2,739	2,677	1,739
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	12,219	12,199	12,111	12,150	11,756	9,372
Retained Earnings	-4,772	-4,878	-5,520	-5,080	-4,423	-3,536
Treasury Stock	-19.75	-19.75	-3.1	-	-	-
Comprehensive Income & Other	-83.03	425.12	137.99	77.23	263.73	-230.85
Total Common Equity	7,344	7,727	6,725	7,148	7,597	5,605
Minority Interest	18.98	22.35	20.63	32.86	47.23	54.36
Shareholders' Equity	7,363	7,749	6,746	7,181	7,644	5,659
Total Liabilities & Equity	10,383	10,824	9,407	9,920	10,321	7,398
Total Debt	1,532	1,611	1,575	1,655	1,540	1,306
Net Cash (Debt)	5,560	5,461	5,425	6,632	7,471	4,940
Net Cash Growth	1.76%	0.66%	-18.20%	-11.22%	51.24%	76.67%
Net Cash Per Share	3.30	3.23	3.20	3.89	5.05	3.62
Filing Date Shares Outstanding	1,764	1,932	1,694	1,690	1,682	1,410
Total Common Shares Outstanding	1,764	1,932	1,694	1,690	1,682	1,410
Working Capital	6,745	6,678	6,771	6,683	7,224	6,088
Book Value Per Share	4.16	4.00	3.97	4.23	4.52	3.98
Tangible Book Value	7,093	7,476	6,464	6,879	7,553	5,567
Tangible Book Value Per Share	4.02	3.87	3.81	4.07	4.49	3.95
Buildings	-	-	-	364.63	224.41	81.04
Machinery	-	405.49	362.86	302.01	248.13	127.57
Construction In Progress	-	115.01	138.86	166.91	197.65	230.72
Leasehold Improvements	-	-	-	-	35.44	6.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.